{"name":"Global Alliance for TB Drug Development","slug":"global-alliance-for-tb-drug-development","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"HRZE","genericName":"HRZE","slug":"hrze","indication":"Tuberculosis (drug-susceptible, pulmonary and extrapulmonary)","status":"phase_3"},{"name":"HR","genericName":"HR","slug":"hr","indication":"Tuberculosis (pulmonary and extrapulmonary)","status":"marketed"},{"name":"Moxifloxacin (M)","genericName":"Moxifloxacin (M)","slug":"moxifloxacin-m","indication":"Community-acquired bacterial pneumonia","status":"marketed"},{"name":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","genericName":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","slug":"moxifloxacin-ethambutol-isoniazid-pyrazinamide-rifampicin","indication":"Tuberculosis (drug-susceptible and multidrug-resistant forms)","status":"phase_3"},{"name":"Pyrazinamide (Z)","genericName":"Pyrazinamide (Z)","slug":"pyrazinamide-z","indication":"Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Rifafour","genericName":"Rifafour","slug":"rifafour","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"HRZE","genericName":"HRZE","slug":"hrze","phase":"phase_3","mechanism":"HRZE is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production.","indications":["Tuberculosis (drug-susceptible, pulmonary and extrapulmonary)"],"catalyst":""},{"name":"HR","genericName":"HR","slug":"hr","phase":"marketed","mechanism":"HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis.","indications":["Tuberculosis (pulmonary and extrapulmonary)"],"catalyst":""},{"name":"Moxifloxacin (M)","genericName":"Moxifloxacin (M)","slug":"moxifloxacin-m","phase":"marketed","mechanism":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.","indications":["Community-acquired bacterial pneumonia","Acute bacterial sinusitis","Acute bacterial exacerbation of chronic bronchitis","Uncomplicated skin and soft tissue infections","Complicated skin and soft tissue infections"],"catalyst":""},{"name":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","genericName":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","slug":"moxifloxacin-ethambutol-isoniazid-pyrazinamide-rifampicin","phase":"phase_3","mechanism":"This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.","indications":["Tuberculosis (drug-susceptible and multidrug-resistant forms)"],"catalyst":""},{"name":"Pyrazinamide (Z)","genericName":"Pyrazinamide (Z)","slug":"pyrazinamide-z","phase":"phase_3","mechanism":"Pyrazinamide is converted to pyrazinoic acid inside Mycobacterium tuberculosis cells, where it disrupts bacterial energy metabolism and nucleic acid synthesis.","indications":["Tuberculosis (TB), including drug-susceptible and multidrug-resistant TB as part of combination therapy"],"catalyst":""},{"name":"Rifafour","genericName":"Rifafour","slug":"rifafour","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNMkp0Tzl2c3hWdlNUQzV0Zmx2eW1OeUtaQXotNGFreGtnMkF0ZVd2T2RRb3FYZ0h3TjByZkZTUDEybzJBc0JkSnJMclBERmhFampqOWItcGhPLWNJRzlBZGI4SHVZMjVDYzVITEhPMnM0N3U2M19mMzlRNG50cGttWkN5TVpLUjktZ0o5WjRVUk1vVGNuZVpSRWNqM1BLeEJQeFpheTlhdjdnM0VIYkRzNl9mZmJOcVRxVEZycWlxQnNtVV8xdThyUy1GNUxzWkM0LUhKNHNrVjZFM0dfU3d4dW9xZE5DQ3JvVTVQMHJqUzBEYkJ2a3VJ?oc=5","date":"2026-02-02","type":"pipeline","source":"lupin.com","summary":"Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases - Lupin | Press Release - lupin.com","headline":"Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Disease","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-02","type":"deal","source":"Medical Dialogues","summary":"Lupin Partners with TB Alliance to Advance Telacebec for TB, Leprosy and Buruli Ulcer - Medical Dialogues","headline":"Lupin Partners with TB Alliance to Advance Telacebec for TB, Leprosy and Buruli Ulcer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-02","type":"pipeline","source":"Express Pharma","summary":"Lupin and TB Alliance collaborate to advance Telacebec for treatment of TB and other mycobacterial diseases - Express Pharma","headline":"Lupin and TB Alliance collaborate to advance Telacebec for treatment of TB and other mycobacterial diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPWEZyd1hOQzFxWFdET2NWN3NmaVRsZ09nVXI2R3ZDdTFfQUwwWGlZVXR1NlhncjMzRTBBYWpiejI1bHZHN1pTeTZoVi1uMkZyRVJZcUUtdXpGT3h3b3R2UmN6R1dBSFdRYnBLcjJmUl9kc2JYSkFfOG85cE5HeDFMNkVEenJDSF9HQXA5QTViSkkzLWUzRy1VVzVsdktoVlREOVRta3Y5VTZ1OThhMmhNQ2ExRVBlZUxTTnpOenVsdUNEUzhaUFZJMkxJel96VHVET3Nzamx0aUlTODdTa1luM2lpejVCOHIyLWNhOVE0amVsOXJILVUtbzU0bVNMUmJ6cFhVOXczal9ZTzlSWG5WQkV2a0JKbW1BbjdJZEoyemY?oc=5","date":"2025-01-22","type":"trial","source":"prnewswire.com","summary":"Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNdHp0MzBtVFVxb1FOS3l3QmRkbUpqMjhzc2hWSmlBdFZYZUpHNlZkRkozcUNidDhjdEFlSHVBWVNOTE5vTGhHczFFc0U0eWI3c2xhUThLVTFfS3BNb0wzRnlSaTN4ZHpZYWlXdXVyeDZRbWpKSjNPTTlabUlaOWJBXzBVVEl4bTI5Z0JWM0N6a0xQdk5mM1VqVlB5U2wxNkVmTW53RzNramRfemV4d0JTNXpVSkd5aVBwOFhsZndDM0ItYnNGMXpLanFmMGtKTGJqMXB5OXcxd3ZiRXM?oc=5","date":"2023-08-09","type":"trial","source":"eatg.org","summary":"PAN-TB collaboration announces the start of a Phase 2 clinical trial to evaluate two novel TB treatment regimens - eatg.org","headline":"PAN-TB collaboration announces the start of a Phase 2 clinical trial to evaluate two novel TB treatment regimens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNZmF5X21uakZndU40Z2JRSThRMlhTTUprS08yNnZBZmh6X29jQklxY0NfUDgwSjVPb0ZjQ3FGWVZDb3lySFQ4aEVGUnJpdUNKX2lOazBMMk9uZkZNOTIzd3NIM042WjdkdWZNY0FaUjZzU2d4U0VxV2paXzVYSGpiQUZHeXJPNG9MaHBTaHRfbzNqZDFMV0FZVUVBdFBBX2o2MVIzR0Uya0Fubk5rSnlSN2JHUWp3SUY0UUdZVEIxaXMyYnk4OEctdQ?oc=5","date":"2023-03-29","type":"pipeline","source":"The Guardian","summary":"Victory over big pharma opens door to cheaper tuberculosis drugs - The Guardian","headline":"Victory over big pharma opens door to cheaper tuberculosis drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBsNFJQd1BiWlBhWkZzMW5aLUNJOHdNS1hCczBvYjcwNDlOZmdKX0N4d0xxQUJFTnJOblRZQndvdU9sMHVfU3k1NDVKZnZpX3VEc0FSSjdyVEFUMmV0U2c0TlI0WVNQZkxIeDdPMG9iLVlHbkh5X1JKRjVR?oc=5","date":"2022-09-12","type":"pipeline","source":"Market.us","summary":"Drug-Resistant Tuberculosis Treatment Market - Market.us","headline":"Drug-Resistant Tuberculosis Treatment Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNaUtiR2lhWmZnQkNRUFQyNVFCb3FNU185VjE5TDVSMm10RldONlA5NHNhN24xeGE5enU1UENibDluekRidG9nTHVMa3RZNE1Nb2dncUlyYm9BRzNaWnp2cnVXYjZoLTFSYkRSREZKN241czN3YjRtcjZPODRTbnM5Q1dwZEYzUF9kQnd0eVh3MnhuRnZfel8zcnFDTlkzdDlkU2NiWXdoQ2tXMzZ6VDBpcdIBtgFBVV95cUxPY1pVRGlSZDhXeVFIOTBYcTc4QzAxSjBjOVZnaVpSeVdqa0Q4SkRSRWctVkUtQ3JXOHdjQUtrOFcwSEh2OTA0ZEtBOGF0N1JjaDNhR0NTOVJFaUh5WUZqbFhzYnVqVVIzV2ZPMy1sT05pNDdWYk9STDJZTnV1NzNKNU5oMDMtOXZhY3doT0lkTDZ5ZC12OG44aFBfZGZSNHFGUkZuSm1aRG1fa0lkSUF6eU9yYWxsUQ?oc=5","date":"2019-08-22","type":"earnings","source":"pbs.org","summary":"Nonprofit drug maker produces TB antibiotic after private companies wouldn't - pbs.org","headline":"Nonprofit drug maker produces TB antibiotic after private companies wouldn't","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNU3JZNUlRdTJJZHNkcmdXUlhnSHlHVWJadjRSNDVUbXNTUFN2OTJUYjBMa2ktSmVmWl92RVVWWU51alcxTjdjdVhUMkN0WVBVMldYMUJ5cjJrMG5sUUtfa0VWaTZ1TzdzalBrcVNoSU9EYjd1RFJCQjRRLV9EbTFuVjlYek1EVEdsZFNQNF9IZUVfX25QSlpfZGUtY0duSGtiTnc?oc=5","date":"2019-03-16","type":"regulatory","source":"C&EN","summary":"US FDA reviewing pretomanid for tuberculosis - C&EN","headline":"US FDA reviewing pretomanid for tuberculosis - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQ3hyakktU1FaSWMwdWRVNkpCV1FsOGVDdTFGLWI3QmgzUUVKRXdyR0tHRkJONFk5NWhQRkk1aXhHVjl2TG45MXhkc0FGTWEtVllmUzlPa21jd1RUbFBfcGVLdFA1ZlBnaDBLalh5bHhVN3BsVG85cy1WR0JJMlBzS05VWUpoNFU1Z2pF?oc=5","date":"2018-04-28","type":"pipeline","source":"The Lancet","summary":"Giorgio Roscigno—senior advisor to the Global Alliance for TB Drug Development - The Lancet","headline":"Giorgio Roscigno—senior advisor to the Global Alliance for TB Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPT21MQk5EVEhTZ205TklWRlRoc2Zmd3hvcXoyWjVuZC0tSHBqNzRfRm5zSXVWZXQ1RzN5eE5SRm5VR2wxMThoMEpQaF85bWM0eUItT3VJTFB5ckY0MkVQZU9ZbERhUlNyaTdKM0NKbzlnUEVZZ0tvTVNGX1h3eG5wZkFtSU52MzhxdWlZa0pGblA5TE5o?oc=5","date":"2014-05-07","type":"deal","source":"Asian Scientist Magazine","summary":"Fosun Pharma Granted License For TB Alliance Drug - Asian Scientist Magazine","headline":"Fosun Pharma Granted License For TB Alliance Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE1LcWxyWUt4UmpvOUMtMnktSE5adXZWdzdBeDlTajFpRW1hMlpVSXNleVFLdmktdy1DVFNQVWpIYTZJTFAyME9vaTdIa3BwLUU?oc=5","date":"2013-10-09","type":"pipeline","source":"Nature","summary":"Drug development: A combined effort - Nature","headline":"Drug development: A combined effort","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":3,"marketed":2,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}